CVKD [NASD]
CADRENAL THERAPEUTICS INC
Index- P/E- EPS (ttm)- Insider Own64.16% Shs Outstand11.63M Perf Week-34.44%
Market Cap29.90M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.55M Perf Month-
Income- PEG- EPS next Q- Inst Own- Short Float / Ratio- / - Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Interest- Perf Half Y-
Book/sh-0.14 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.60 - 6.75 Perf YTD-37.62%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.93% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low-1.15% ATR1.04
Employees1 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility11.82% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.07 Prev Close2.62
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.80M Price2.57
Recom- SMA20-21.33% SMA50-21.33% SMA200-21.33% Volume118,449 Change-1.91%
Jan-24-23 02:11PM
Jan-23-23 11:39AM
08:30AM
Jan-20-23 09:31AM
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.